Patents by Inventor Smita S. Chandran

Smita S. Chandran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T CELL RECEPTORS TARGETING RAS MUTATIONS AND USES THEREOF
    Publication number: 20240091361
    Abstract: The presently disclosed subject matter provides novel T cell receptors (TCRs) that target a mutated RAS protooncogene. The presently disclosed subject matter further provides cells comprising such TCRs, and methods of using such cells for treating cancers associated with RAS.
    Type: Application
    Filed: November 22, 2023
    Publication date: March 21, 2024
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Christopher A. KLEBANOFF, Smita S. CHANDRAN
  • T CELL RECEPTORS TARGETING PIK3CA MUTATIONS AND USES THEREOF
    Publication number: 20220110976
    Abstract: The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., breast cancer). It relates to mutant PIK3CA-targeted TCRs that specifically target a mutant PIK3CA peptide (e.g., a human mutant PIK3CA peptide), and immunoresponsive cells comprising such TCRs. The presently disclosed mutant PIK3CA peptide-specific TCRs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Application
    Filed: December 17, 2021
    Publication date: April 14, 2022
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Christopher A. Klebanoff, Smita S. Chandran
  • METHODS FOR IDENTIFYING ANTIGEN-SPECIFIC T CELL RECEPTORS
    Publication number: 20210060075
    Abstract: The presently disclosed subject matter provides in vitro methods for identify TCRs that target specific antigens. The presently disclosed subject matter further provides TCRs identified by the methods and immunoresponsive cells comprising such TCRs.
    Type: Application
    Filed: November 11, 2020
    Publication date: March 4, 2021
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Christopher A. Klebanoff, Smita S. Chandran
  • T CELL RECEPTORS TARGETING PIK3CA MUTATIONS AND USES THEREOF
    Publication number: 20210060076
    Abstract: The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., breast cancer). It relates to mutant PIK3CA-targeted TCRs that specifically target a mutant PIK3CA peptide (e.g., a human mutant PIK3CA peptide), and immunoresponsive cells comprising such TCRs. The presently disclosed mutant PIK3CA peptide-specific TCRs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Application
    Filed: November 11, 2020
    Publication date: March 4, 2021
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Christopher Klebanoff, Smita S. Chandran